Vaxcyte Appoints Whitney Jones as Chief People Officer
16 Janeiro 2024 - 6:01PM
Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases, today announced the
appointment of Whitney Jones as Chief People Officer. Ms. Jones
will lead Vaxcyte’s human resources strategy and operations,
including people and culture, talent acquisition and management,
learning and development, total rewards and employee engagement.
“At Vaxcyte, we are proud to cultivate a culture that values
collaboration, innovation and a shared commitment to our mission,”
said Grant Pickering, Chief Executive Officer and Co-founder of
Vaxcyte. “We have built an extraordinary team, and we recognize
that our success is intricately tied to the strength and well-being
of our people. Whitney’s role as our Chief People Officer will be
instrumental in championing our people-first approach and ensuring
that our workforce continues to grow and thrive.”
“We’re thrilled to welcome Whitney to Vaxcyte as our first Chief
People Officer,” said Andrew Guggenhime, President and Chief
Financial Officer of Vaxcyte. “She’s an accomplished leader with an
impressive background of successfully leading people strategies for
fast-growth and established companies across a breadth of
industries. Whitney will play an important role in maintaining our
strong company culture and supporting our organizational growth
strategies as we scale the Company to advance our pipeline of novel
vaccine candidates, including our lead pneumococcal conjugate
vaccine franchise programs, VAX-24 and VAX-31.”
“I’m delighted to join Vaxcyte, a mission-driven company working
to address serious bacterial infections to protect every child born
and every adult at risk across the globe,” said Ms. Jones. “It’s a
time of incredible growth for the Company and I’m honored to work
alongside such a talented team as we work to realize Vaxcyte’s
long-term vision. I look forward to fostering the well-established
dynamic and vibrant culture as we continue to scale and prepare for
the anticipated global commercialization of potentially life-saving
vaccines.”
About Ms. JonesMs. Jones is a seasoned
executive with over 20 years of experience spanning biotech,
healthcare diagnostics, financial technology and retail with
extensive expertise in human resources strategy and operations. Ms.
Jones joins Vaxcyte from Sangamo Therapeutics where she served as
Senior Vice President and Chief People Officer, overseeing people
and culture, talent and acquisition, learning and development and
human resources operations. Prior to joining Sangamo in 2020, Ms.
Jones was the Chief People Officer at LendingClub, a marketplace
lending company, where she was responsible for all aspects of the
Company’s people strategy. Earlier in her career, Ms. Jones served
as the Global Head of Human Resources at Novartis Diagnostics and
from 2000-2013 held roles of increasing responsibility in human
resources at Gap, Inc. Ms. Jones earned her Bachelor of Arts in
History with a minor in French from the University of Vermont.
About VaxcyteVaxcyte is a vaccine innovation
company engineering high-fidelity vaccines to protect humankind
from the consequences of bacterial diseases. The Company is
developing broad-spectrum conjugate and novel protein vaccines to
prevent or treat bacterial infectious diseases. Vaxcyte’s lead
candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing
PCV being developed for the prevention of IPD and is proceeding to
Phase 3. VAX-31, the Company’s next-generation 31-valent PCV, is
the broadest-spectrum PCV candidate in the clinic today.
Vaxcyte is re-engineering the way highly complex vaccines are
made through modern synthetic techniques, including advanced
chemistry and the XpressCF™ cell-free protein synthesis platform,
exclusively licensed from Sutro Biopharma, Inc. Unlike conventional
cell-based approaches, the Company’s system for producing
difficult-to-make proteins and antigens is intended to accelerate
its ability to efficiently create and deliver high-fidelity
vaccines with enhanced immunological benefits. Vaxcyte’s pipeline
also includes VAX-A1, a prophylactic vaccine candidate designed to
prevent Group A Strep infections; VAX-PG, a therapeutic vaccine
candidate designed to slow or stop the progression of periodontal
disease; and VAX-GI, a vaccine program designed to prevent
Shigella. Vaxcyte is driven to eradicate or treat invasive
bacterial infections, which have serious and costly health
consequences when left unchecked. For more information, visit
www.vaxcyte.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. These statements
include, but are not limited to, statements related to the
potential benefits of VAX-24 and VAX-31, including breadth of
coverage and clinical potential; the potential of Vaxcyte’s
carrier-sparing, cell-free platform technology; the anticipated
global commercialization of Vaxcyte’s potentially life-saving
vaccines; and other statements that are not historical fact. The
words “anticipate,” “believe,” “could,” “expect,” “intend,” “may,”
“on track,” “potential,” “should,” “would” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) convey uncertainty of future events or
outcomes and are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements are based
on Vaxcyte’s current expectations and actual results and
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of risks and
uncertainties, including, without limitation, risks related
to Vaxcyte’s product development programs, including
development timelines, success and timing of chemistry,
manufacturing and controls and related manufacturing activities,
potential delays or inability to obtain and maintain required
regulatory approvals for its vaccine candidates, and the risks and
uncertainties inherent with preclinical and clinical development
processes; the success, cost and timing of all development
activities and clinical trials; and sufficiency of cash and other
funding to support Vaxcyte’s development programs and other
operating expenses. These and other risks are described more fully
in Vaxcyte’s filings with the Securities and Exchange Commission
(SEC), including, without limitation, its Quarterly Report on Form
10-Q filed with the SEC on November 6, 2023 or in other documents
Vaxcyte subsequently files with or furnishes to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made and are based on
management’s assumptions and estimates as of such date, and readers
should not rely upon the information in this press release as
current or accurate after its publication date. Vaxcyte undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations. Readers should not rely upon
the information in this press release as current or accurate after
its publication date.
Contacts:
Janet Graesser, Vice President, Corporate Communications and
Investor RelationsVaxcyte, Inc.917-685-8799media@vaxcyte.com
Jennifer Zibuda, Senior Director, Investor RelationsVaxcyte,
Inc.860-729-8902investors@vaxcyte.com
Vaxcyte (NASDAQ:PCVX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Vaxcyte (NASDAQ:PCVX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024